ROCKVILLE, Md.–Two officials from Novavax Inc. announced Jan. 25 that they will be presenting at Phacilitate’s eighth annual Vaccine Forum Washington 2010.
The conference will take place Jan. 25-27 at the Grand Hyatt, Washington, D.C.
John Trizzino, senior vice president of international and government alliances, will be participating in a focus session, “Fast tracking the development of — and path to licensure for — a novel manufacturing platform by utilizing it in pandemic influenza efforts.” The session begins at 4:15 p.m. Jan. 26.
Rahul Singhvi, president and CEO will be presenting a case study, “Small Company/Big Company interplay: How does it all connect around manufacturing, supply chain, and the need for dose sparing” It will begin at 12:55 p.m. Jan. 27.
Novavax is a clinical-stage biotechnology company creating novel vaccines.
The conference program features a mixture of business, regulatory, investment and public policy topics, with the speaker panel featuring representatives of vaccine developers, as well as key government agencies, non-government agencies and analysts.
For more information visit: www.phacilitate.co.uk.